🩸Cytovale’s Sepsis Risk Test: A Game-Changer for Emergency Rooms
Cytovale, a San Francisco-based biotech firm, has recently secured $184 million in funding to expand the reach of its innovative sepsis risk test, IntelliSep, into more emergency rooms (ERs) across the United States. Sepsis, a life-threatening response to infection, requires rapid diagnosis and treatment to improve patient outcomes. IntelliSep aims to address this critical need by providing a quick and reliable method to assess sepsis risk in patients.
IntelliSep is a blood-based, semi-quantitative test that uses high-speed imaging and machine learning to evaluate cell morphology and measure immune cell activation. The test involves microfluidics and deformability cytometry to observe changes in leukocyte biophysical properties, providing a score between 0.1 and 10 to indicate the probability of sepsis. This score, combined with other clinical assessments, aids in the early detection of sepsis, potentially saving lives and reducing healthcare costs.
Clinical studies have shown that IntelliSep can deliver results in less than 10 minutes, significantly faster than traditional methods1. The test has been used to evaluate over 7,000 patients at Our Lady of the Lake Regional Medical Center in Louisiana, demonstrating reductions in patient length-of-stay and healthcare costs1. With the recent funding, Cytovale plans to expand the commercial use of IntelliSep, aiming to make it a standard tool in ERs nationwide.
The potential impact of IntelliSep on emergency care cannot be overstated. Sepsis is a global health challenge, and early detection is crucial for effective treatment. Cytovale’s innovative approach, combining advanced imaging techniques with machine learning, represents a significant leap forward in sepsis diagnostics.
However, the success of IntelliSep will depend on its adoption by healthcare providers. While the clinical benefits are clear, integrating new technology into existing workflows can be challenging. Cytovale’s efforts to provide 24-hour technical support and expand its implementation teams are commendable steps towards ensuring smooth adoption.
Moreover, the financial backing Cytovale has received is a strong vote of confidence in its technology. The $184 million in funding will not only support the expansion of IntelliSep but also enable further research to validate its efficacy across diverse healthcare settings. This is crucial for gaining widespread acceptance and demonstrating the test’s value in improving patient outcomes and reducing costs.
In conclusion, Cytovale’s IntelliSep has the potential to revolutionize sepsis diagnosis in emergency rooms. With continued support and successful integration into healthcare systems, it could become an indispensable tool in the fight against sepsis, ultimately saving lives and reducing the burden on healthcare systems.
🚨WHO Adds Cepheid Mpox Tests to Emergency-Use List
The World Health Organization (WHO) has recently added the Cepheid Xpert Mpox test to its Emergency Use Listing (EUL) procedure, a significant step in enhancing global diagnostic capabilities for mpox (formerly known as monkeypox). This move is part of WHO’s ongoing efforts to ensure access to quality-assured testing options, particularly in low- and middle-income countries (LMICs).
The Xpert Mpox test is a real-time Polymerase Chain Reaction (PCR) assay designed to detect the viral DNA of monkeypox virus clade II1. It operates on the GeneXpert system, a near-point-of-care testing platform that supports decentralized testing. The test is fully automated and delivers results in under 40 minutes, making it a rapid and reliable option for diagnosing mpox.
In addition to the Cepheid test, WHO has also listed the cobas MPXV assay developed by Roche Molecular Systems. This PCR-based test is intended for use on the cobas 6800/8800 systems and can detect both clades of the mpox virus, providing results in under two hours. These tests are crucial for timely diagnosis and treatment, helping to contain the spread of the virus and manage outbreaks more effectively.
The inclusion of Cepheid’s Xpert Mpox test in WHO’s Emergency Use Listing is a pivotal development in the fight against mpox. Rapid and accurate diagnostics are essential for controlling infectious diseases, and the Xpert Mpox test offers a significant advantage with its quick turnaround time and ease of use.
However, the real challenge lies in the implementation and accessibility of these tests, especially in resource-limited settings. While the GeneXpert system is designed for decentralized testing, ensuring that healthcare facilities in LMICs have the necessary infrastructure and training to use these tests effectively is critical1. WHO’s efforts to work with national regulatory authorities and manufacturers to facilitate domestic registration and fast-track approvals are commendable steps towards this goal.
The addition of the cobas MPXV assay further strengthens the diagnostic arsenal against mpox. Its ability to process multiple samples simultaneously makes it suitable for high-volume testing environments, which is particularly beneficial during outbreaks1. The combination of these advanced diagnostic tools will undoubtedly enhance global response capabilities.
In conclusion, WHO’s listing of the Cepheid Xpert Mpox test and the cobas MPXV assay represents a significant advancement in mpox diagnostics. With continued support and effective implementation, these tests have the potential to greatly improve the management and control of mpox outbreaks, ultimately saving lives and reducing the burden on healthcare systems worldwide.
💸Breath Diagnostics Secures $1M to Advance Breath-Based Testing Platform
Breath Diagnostics, a medical device firm based in Louisville, Kentucky, has successfully closed a $1 million convertible note financing round. This funding will be pivotal in supporting the company’s operations and accelerating the research and development of its innovative breath-based testing platform, OneBreath.
The OneBreath platform is designed to detect lung cancer and other diseases by capturing target biomarkers from breath samples using advanced microchip reactor technology. These samples are then analyzed using ultra-high performance liquid chromatography-mass spectrometry (LC-MS), providing a non-invasive and efficient diagnostic method.
In addition to the financing news, Breath Diagnostics has appointed Aaron Roebuck as the new company president. Roebuck, who previously served as the senior director of clinical sciences at Vero Biotech, brings extensive experience in next-generation drug delivery systems. His leadership is expected to drive the development and commercialization of the OneBreath platform.
Roebuck expressed his enthusiasm for the project, stating, "OneBreath has the potential to significantly improve early detection of diseases like lung cancer and pneumonia. I look forward to helping lead the company’s efforts as we move toward the ever-important commercialization phase".
This financing round, led by strategic investors including Breath Diagnostics CEO Ivan Lo, marks a significant milestone for the company. With the new funds, Breath Diagnostics aims to bring its cutting-edge technology closer to market, offering a promising tool for early disease detection and improved patient outcomes.
❓EU Parliament Supports IVD Regulation Review, Next Steps Uncertain
The European Parliament has recently passed a resolution supporting a review of the In Vitro Diagnostics Regulation (IVDR), but the path forward remains unclear. This decision highlights the need for significant changes to the current regulatory framework, which has faced criticism for its complexity and the burdens it places on manufacturers.
The resolution calls on the European Commission and EU member states to address ongoing concerns about the IVDR, which was enacted in 2017 to replace the 1998 IVD Directive. The IVDR introduced a more stringent classification system for in vitro diagnostic devices, requiring oversight by EU-designated notified bodies1. However, the transition has been fraught with challenges, including regulatory capacity issues and extended compliance deadlines.
MedTech Europe, a trade association representing medical device manufacturers, has welcomed the resolution. Miriam D’Ambrosio, head of communications at MedTech Europe, emphasized the political significance of the vote, stating,
"The resolution shows the political willingness to revise the medical technology regulations. Now it’s in the hands of the member states to take the next steps"
The European Parliament has urged the Commission to propose delegated and implementing acts by the end of the first quarter of 2025 to address the most pressing challenges. These include streamlining regulatory procedures, providing predictable timelines for certification, and supporting small- and medium-sized enterprises (SMEs) in the certification process.
Despite the resolution’s support, the immediate impact remains uncertain. Industry groups like MedTech Europe and Germany’s diagnostics industry association, VDGH, have expressed concerns about the bureaucratic hurdles and unpredictable timelines under the current framework. They advocate for a comprehensive reform to ensure the availability of diagnostics and maintain Europe’s competitiveness in the global market.
As the European Commission and member states deliberate on the next steps, stakeholders in the medical device industry will be closely monitoring developments. The outcome of this review could have significant implications for the future of in vitro diagnostics in Europe.
🤝UK Government Budget 2024: A Boost for Biotech and Life Sciences
This week, Chancellor Rachel Reeves presented the UK government’s 2024 budget, unveiling a series of measures aimed at strengthening the biotech and life sciences sectors. The budget reflects a commitment to fostering innovation, supporting research and development (R&D), and enhancing the National Health Service (NHS) infrastructure.
Significant R&D Investment
One of the standout features of the budget is the record £20.4 billion investment in R&D. This funding is set to bolster the UK’s scientific research capabilities and drive economic growth. A key component of this investment is the Life Sciences Innovative Manufacturing Fund (LSIMF), which will receive an initial £70 million in grants for 2025-26, with a long-term commitment of up to £520 million. This initiative is expected to attract up to £1.8 billion in private investment, creating thousands of high-skilled jobs and accelerating the development of life-saving treatments.
Support for SMEs and Start-Ups
Recognizing the vital role of small- and medium-sized enterprises (SMEs) and start-ups in the biotech sector, the budget allocates £40 million over five years to the Proof of Concept Fund. This fund aims to help researchers transform innovative ideas into successful businesses, fostering job creation and economic growth.
R&D Tax Relief
The government has also committed to maintaining the current rates of R&D tax relief, which are among the most generous in the G7. This move is designed to support large companies and enhance the administration of R&D reliefs, improving the customer experience and reducing errors and fraud.
Horizon Europe Association
The budget fully funds the UK’s association with Horizon Europe, the world’s largest collaborative funding scheme for research and innovation. This association provides UK scientists and innovators access to over £80 billion for cutting-edge projects, reinforcing the UK’s leading research base.
Enhancements to Health and Clinical Research
The Department of Health and Social Care will receive a capital budget uplift of £3.1 billion, ensuring a real terms increase in funding for the National Institute for Health and Care Research (NIHR). This investment will strengthen the UK’s clinical trial network, support better patient outcomes, and bolster the life sciences investment environment.
Industry Reactions
Industry leaders have praised the budget for its focus on life sciences. Steve Bates, CEO of the BioIndustry Association (BIA), stated,
"Today’s Budget rightly puts the life sciences sector at the heart of UK economic growth. In a tough fiscal environment, Chancellor Rachel Reeves recommitted to R&D tax credits at current rates for this parliament"
As the UK government continues to prioritize science and technology, the biotech and life sciences sectors are poised for significant growth. These investments will not only advance scientific research but also create high-quality jobs and improve public health.
🚨We Need Your Help!🚨
If you enjoy the content we produce and find our newsletter valuable, we have a small favour to ask. Please share this newsletter with just one person and encourage them to sign up. Your support helps us grow and continue delivering the latest updates and insights in the biotech and life sciences sectors.
We really appreciate your support! Thank you for being a part of our community. 🌟
Nathan 😁